As pointed out in ref. 15, most of the mutations in TP53 were clonal for both adenocarcinoma and squamous-cell carcinoma in the TRACERx dataset, whereas mutations in CDKN2A appeared mostly in the latter subtype and often late. This evidence concerns the gene CDKN2A and squamous cell carcinoma.